Related Experiment Videos
Implementing an i.v. iron maintenance regimen protocol in a hemodialysis practice
Cheryl Gilmartin1, Kwanta Na-Thalang, Jose Arruda
1University of Illinois at Chicago, Chicago, IL, USA.
Summary
Iron-deficiency anemia is common in end-stage renal disease (ESRD) patients on hemodialysis. Recombinant human erythropoietin (EPO) use further worsens iron deficiency, affecting up to 90% of patients.
Area of Science:
- Nephrology
- Hematology
Background:
- Iron-deficiency anemia is prevalent in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis.
- Multiple factors contribute to iron deficiency, including blood loss from procedures, gastrointestinal bleeding, and poor nutrient intake.
- Recombinant human erythropoietin (EPO) therapy, used to stimulate red blood cell production, exacerbates functional iron deficiency.
Purpose of the Study:
- To summarize the causes and complications of iron-deficiency anemia in ESRD patients on hemodialysis.
- To highlight the impact of EPO therapy on iron status in this patient population.
Main Methods:
- Literature review of studies on iron metabolism and anemia in ESRD patients.
- Analysis of factors contributing to iron loss and functional iron deficiency.
Main Results:
- ESRD patients on hemodialysis experience significant blood loss through various means.
- EPO therapy increases erythropoiesis, leading to a higher demand for iron.
- Functional iron deficiency is observed in up to 90% of patients treated with EPO.
Conclusions:
- Iron-deficiency anemia is a complex issue in ESRD patients on hemodialysis.
- EPO therapy necessitates careful monitoring and management of iron status to prevent or treat functional iron deficiency.